30966 Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cancer Detection and Therapy. 

Date: July 7, 2021. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Laura Asnaghi, Ph.D., 

Scientific Review Officer, National Institutes 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Room 6200, MSC 7804, 

Bethesda, MD 20892, (301) 443–1196, 

laura.asnaghi@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 4, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–12144 Filed 6–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Collaborative Research Projects (PAR–18– 

951). 

Date: July 21, 2021. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Rajiv Kumar, Ph.D., 

Branch Chief, Blood and Vascular Branch, 

Office of Scientific Review/DERA, National 

Heart, Lung, and Blood Institute, 6705 

Rockledge Drive, 208–W, Bethesda, MD 

20892, 301–827–4612, rajiv.kumar@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: June 4, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–12141 Filed 6–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Benjamin Hurley; tel. 240–669–5092; 

benjamin.hurley@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Producing Modified Vaccinia Ankara 

(MVA) Virus with Continuous 

Mammalian Cell Lines: Viral Host-range 

Factors for Increasing MVA Vaccine 

Production Yield Description of 

Technology: 

Modified vaccinia Ankara (MVA) 

based vaccines are being deployed in 

numerous human clinical trials for 

indications such as measles, malaria, 

HIV–1 and MERS to name a few. As 

with many vaccines, scale-up and 

production are significant challenges 

with the MVA platform. Not only are 

current large-scale MVA vaccine 

production processes inefficient (such 

as the cumbersome use of chick embryo 

fibroblast (CEF) cells), but a major 

bottleneck lies in limited host cell 

propagation options and a lack of viable 

continuous cell lines suitable for MVA 

vaccine production. 

To address this need, scientists at 

NIAID have identified a number of key 

viral factors in MVA replication in 

mammalian cells and developed 

methods of modifying MVA viruses in 

a way that allows for the growth of MVA 

in cells that were previously considered 

unsuitable for such purpose. For 

example, NIAID scientists observed that 

the introduction of a serine protease 

inhibitor 1 (SPI–1) gene into the MVA 

genome led to more than a 2-log 

enhancement of virus spread in human 

diploid MRC–5 cells, whereas deletion 

of the gene diminished the spread of 

host-range extended viruses by similar 

extents. Additionally, MRC–5 cells 

stably expressing SPI–1 also enhanced 

replication of MVA. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Vaccine Development: Recombinant 

MVA-based vaccine production in nonCEF cell lines. 

• Therapeutic oncolytic virus: 

Recombinant MVA constructs encoding 

oncolytic tumor-suppressor proteins, 

pro-apoptotic proteins, cytokines, 

immunomodulatory proteins, cytotoxic 

peptides, suicide proteins, cytotoxins, 

pro-drugs, therapeutic RNAs, etc. 

Competitive Advantages: 

• Recombinant MVA constructs for 

use in non-avian, continual cell linemediated vaccine production. 

• Efficient scale-up vaccine 

production as a result of higher viral 

yield, enhancing epidemic/pandemic 

preparedness. 

Inventors: Bernard Moss, Linda Wyatt, 

Ruikang Liu, Jorge Mendez-Rios, all of 

NIAID. 

Publications: 

Liu R, Mendez-Rios JD, Peng C, et al. SPI– 

1 is a missing host-range factor required 

for replication of the attenuated modified 

vaccinia Ankara (MVA) vaccine vector in 

human cells.; PLoS Pathog. 2019. 

Peng C, Moss B. Repair of a previously 

uncharacterized second host-range gene 

contributes to full replication of 

modified vaccinia virus Ankara (MVA) 

in human cells. Proc Natl Acad Sci U S 

A. 2020. 

Intellectual Property: HHS Reference 

No. E–076–2019; International 

Application No. PCT/US20/33788. 

Licensing Contact: To license this 

technology, please contact Benjamin 


khammond on DSKJM1Z7X2PROD with NOTICES